Skip to main content
Clinical Trials/NCT03307070
NCT03307070
Completed
Not Applicable

Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury

Massachusetts General Hospital1 site in 1 country62 target enrollmentSeptember 23, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Major Depressive Disorder
Sponsor
Massachusetts General Hospital
Enrollment
62
Locations
1
Primary Endpoint
Feasibility - randomization, recruitment rates
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Cognitive behavioral therapy for major depressive disorder (MDD) was adapted for individuals with moderate to severe traumatic brain injury (TBI) (CBT-TBI). A structured, treatment manual was developed.

The primary aim is to evaluate the acceptability and tolerability of, and adherence to, CBT-TBI in a randomized waitlist-controlled, 12-week pilot trial (N=40).

The exploratory aim is to evaluate the potential efficacy of CBT-TBI for MDD in the randomized pilot trial (N=40) and possible moderators and mediators of outcome.

Detailed Description

The primary aim of this study is to develop a highly acceptable, manualized treatment (CBT-TBI) for MDD in patients with moderate to severe TBI. Initial feasibility data from a small, open pilot will inform the randomized controlled trial. Primary analyses will examine feasibility and acceptability of the intervention. The investigators will then pilot test the efficacy of the intervention to reduce depressive symptoms (IDS-C) after 12 weeks compared to a waitlist control group. The proposed study involves the following points of contact: (1) Obtaining informed consent and screening (may be broken up into multiple visits), (2) biweekly clinician assessments of depressive and neuropsychiatric symptoms (weeks 2, 4, 6, 8, 10), (3) weekly self-report assessments of depressive symptoms for those receiving the intervention, (4) 12 weekly individual CBT-TBI sessions for those randomized to the intervention, (5) a comprehensive assessment at week 12 (primary endpoint), which includes the neuropsychological battery, and (6) a 3-month follow-up assessment for those who received the intervention. The week 12 visit can be split into two parts, with the neuropsychological assessment occurring during the second part, in order to accommodate subjects' potential limitations due to fatigue. Procedures for this study were all conducted remotely after March 17, 2020.

Registry
clinicaltrials.gov
Start Date
September 23, 2017
End Date
November 28, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Lauren Fisher

Clinical Psychologist

Massachusetts General Hospital

Eligibility Criteria

Inclusion Criteria

  • Adults aged 18 and older
  • English language proficiency
  • Ability to provide written, informed consent; OR consent provided by legally authorized representative with assent from subject
  • Ability to see and hear (hearing or visual loss cannot impair ADLs or in-room conversation)
  • Has access to a smartphone/tablet/computer with internet and video capabilities for virtual sessions
  • Having been hospitalized for moderate to severe TBI that occurred at least 3 months prior to study entry
  • Meeting ANY ONE of the following severity criteria, as documented in electronic medical record (EPIC) or available outside records:
  • GCS 3-12 with GCS motor score ≤ 5 within 4 hours after injury
  • GCS 3-12 with GCS motor score =6 within 4 hours after injury AND documented intracranial abnormalities on imaging
  • GCS 13-15 within 4 hours after injury AND documented intracranial abnormalities on imaging

Exclusion Criteria

  • Uncontrolled medical illness
  • Behavioral dyscontrol, defined as the presence of verbally or physically aggressive behavior in the past month, as evidenced in medical records, pre-screening interviews, or observed by any study staff
  • Presents with PTSD as the primary diagnosis, as determined by a clinician
  • Substance use disorder, moderate or severe, within the past 6 months
  • Has bipolar disorder, a primary psychotic disorder or current psychotic symptoms, or acute suicidality or homicidality
  • Currently receiving regular (≥ 2 times/ mo.) psychosocial treatment for depression
  • Has participated in CBT for depression within the past 6 months
  • Individuals with history of dementia or severe cognitive impairment that is not related to TBI (e.g., cognitive impairment requiring assistance with basic activities of daily living, such as getting ready in the morning)

Outcomes

Primary Outcomes

Feasibility - randomization, recruitment rates

Time Frame: 12 weeks

For examining the feasibility of treatment with CBT-TBI, descriptive analyses will be conducted to assess rate of recruitment and randomization (number randomized/number consented).

Acceptability - satisfaction with treatment

Time Frame: 12 weeks

Descriptive analyses will be conducted to assess participants' satisfaction with CBT-TBI (Satisfaction with Therapy and Therapist Scale - Revised).

Feasibility - retention/completion rates

Time Frame: 12 weeks

For examining the feasibility of treatment with CBT-TBI, descriptive analyses will be conducted to assess participants' retention/completion rates across study visits.

Feasibility - drop out rates

Time Frame: 12 weeks

For examining the feasibility of treatment with CBT-TBI, descriptive analyses will be conducted to assess participants' drop-out rates across study visits.

Secondary Outcomes

  • Efficacy - Treatment Response [Inventory of Depressive Symptomatology - Clinician Rated (IDS-C)] (Exploratory Aim)(12 weeks)

Study Sites (1)

Loading locations...

Similar Trials